Related Experiment Video

Updated: Jun 5, 2026

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

Janus kinase 2 regulates Bcr-Abl signaling in chronic myeloid leukemia

A Samanta1, B Perazzona, S Chakraborty

  • 1Department of Molecular Pathology, M.D. Anderson Cancer Center, Houston, TX 77054, USA.

Leukemia
|December 25, 2010
PubMed

Insights

Janus kinase 2 (Jak2) inhibition overcomes imatinib resistance in chronic myeloid leukemia (CML) by reducing Bcr-Abl protein levels and oncogenic signaling. Jak2 targets Bcr-Abl phosphorylation, impacting CML cell stability and pathways.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Imatinib mesylate (IM) is effective in early chronic phase chronic myeloid leukemia (CML).
  • Drug resistance to IM and other kinase inhibitors emerges in later stages of CML.
  • The mechanisms underlying IM resistance in CML are not fully understood.

Purpose of the Study:

  • To investigate the role of Janus kinase 2 (Jak2) in overcoming imatinib resistance in Bcr-Abl positive (Bcr-Abl+) CML cells.
  • To elucidate the mechanism by which Jak2 influences Bcr-Abl protein stability and signaling.

Main Methods:

  • Jak2 knockdown and overexpression experiments in Bcr-Abl+ cells.
  • Treatment with Jak2 inhibitors (TG101209/WP1193) and imatinib.
  • In vitro kinase assays using recombinant Jak2 and Bcr-Abl.
  • Analysis of Bcr-Abl protein levels, Tyr177 phosphorylation, and downstream signaling pathways (Ras, PI-3 kinase, STAT5).

Main Results:

  • Jak2 inhibition or knockdown reduced Bcr-Abl protein levels and Tyr177 phosphorylation in Bcr-Abl+ cells.
  • Jak2 directly phosphorylated Tyr177 of Bcr-Abl in vitro.
  • Jak2 inhibition decreased pTyr177 Bcr-Abl but did not affect Bcr-Abl levels, indicating separate mechanisms.
  • Jak2 inhibition diminished Ras, PI-3 kinase pathway activation, and reduced pTyrSTAT5 levels.
  • Jak2 overexpression rescued the effects of Jak2 knockdown.

Conclusions:

  • Jak2 plays a critical role in maintaining Bcr-Abl stability and oncogenic signaling in CML cells.
  • Targeting Jak2 represents a potential strategy to overcome imatinib resistance in CML.
  • Jak2 inhibition affects both Bcr-Abl phosphorylation and protein stability, impacting multiple oncogenic pathways.

More Related Videos

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

Related Concept Videos

The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Anaphase Promoting Complex00:50

Anaphase Promoting Complex

The stepwise destruction of specific proteins is necessary for the progression and completion of the cell cycle. Such proteins are ubiquitinated by ubiquitin ligases and then subsequently destroyed by the proteasome. The SCF (Skp1/Cullin/F-box) and the anaphase-promoting complex (APC) are two important ubiquitin ligases involved in cell cycle progression. While SCF is active throughout the cell cycle, APC gets activated during metaphase to anaphase transition. Cdc20 or Cdh1 binds to APC and...